T1	Participants 76 115	patients with hematologic malignancies.
T2	Participants 219 258	patients with hematologic malignancies.
T3	Participants 325 397	Seventy immunocompromised febrile patients with hematologic malignancies
T4	Participants 433 477	vancomycin therapeutic drug monitoring group
